Literature DB >> 18828174

Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.

Kyle G Grant1, David M Krisky, Mohammed M Ataai, Joseph C Glorioso.   

Abstract

Herpes simplex virus type 1 (HSV-1) represents an attractive vehicle for a variety of gene therapy applications. To render this virus safe for clinical use, its cytotoxic genes must be removed without losing its ability to express transgenes efficiently. Our vectors are deleted for the essential immediate early genes ICP4 and ICP27. These genes are controlled by unique promoters having enhancer elements responsive to a viral structural protein VP16. The expression of these genes occurs prior to the activation of all other lytic functions and is thus required to initiate and complete the virus replication cycle. For large scale manufacture of clinical grade vectors, efficient cell lines must be generated that express the essential viral gene products in trans during vector propagation. Here we describe methods for engineering HSV-1 production cell lines that improve vector growth by altering the kinetics of complementing gene expression. We examined the ability of Vero cells independently transduced with ICP4 and ICP27 under transcriptional control of their respective promoters to support the growth of a replication defective vector (JDTOZHE), deleted for ICP4, ICP27 and approximately 20 kb of internal elements that are not required for virus growth in Vero cells. Vector yield on this cell line was 3 logs lower than wild-type virus grown on Vero cells. To understand the mechanism underlying poor vector yield, we examined the expression of ICP4 and ICP27 during virus complementation. While ICP27 was expressed immediately on vector infection, the expression of ICP4 was considerably delayed by 8-10 h, suggesting that the ICP4 promoter was not adequately activated by VP16 delivered by the infectious vector particle. Use of the ICP0 promoter to express ICP4 from the cellular genome resulted in higher induction levels and faster kinetics of ICP4 expression and a 10-fold improvement in vector yield. This study suggests that vector complementation is highly dependent on the kinetics of complementing gene expression and can lead to large differences in vector yield.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18828174     DOI: 10.1002/bit.22123

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.

Authors:  Yoshitaka Miyagawa; Pietro Marino; Gianluca Verlengia; Hiroaki Uchida; William F Goins; Shinichiro Yokota; David A Geller; Osamu Yoshida; Joseph Mester; Justus B Cohen; Joseph C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

2.  Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain.

Authors:  Y Wang; M O Nowicki; X Wang; W D Arnold; S A Fernandez; X Mo; J Wechuk; D Krisky; J Goss; D Wolfe; P G Popovich; S Lawler; E A Chiocca
Journal:  Gene Ther       Date:  2012-12-13       Impact factor: 5.250

Review 3.  Viral vectors and delivery strategies for CNS gene therapy.

Authors:  Steven J Gray; Kenton T Woodard; R Jude Samulski
Journal:  Ther Deliv       Date:  2010-10

Review 4.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13

Review 5.  New Tools for Epilepsy Therapy.

Authors:  Chiara Falcicchia; Michele Simonato; Gianluca Verlengia
Journal:  Front Cell Neurosci       Date:  2018-05-29       Impact factor: 5.505

6.  Transcriptomic study of Herpes simplex virus type-1 using full-length sequencing techniques.

Authors:  Zsolt Boldogkői; Attila Szűcs; Zsolt Balázs; Donald Sharon; Michael Snyder; Dóra Tombácz
Journal:  Sci Data       Date:  2018-11-27       Impact factor: 6.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.